Logo image of RNA

AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis

NASDAQ:RNA - Nasdaq - US05370A1088 - Common Stock - Currency: USD

29.45  +0.93 (+3.26%)

Premarket: 30 +0.55 (+1.87%)

Fundamental Rating

4

Overall RNA gets a fundamental rating of 4 out of 10. We evaluated RNA against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RNA as it has an excellent financial health rating, but there are worries on the profitability. RNA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RNA had negative earnings in the past year.
In the past year RNA has reported a negative cash flow from operations.
In the past 5 years RNA always reported negative net income.
In the past 5 years RNA always reported negative operating cash flow.
RNA Yearly Net Income VS EBIT VS OCF VS FCFRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

RNA has a better Return On Assets (-20.61%) than 78.70% of its industry peers.
RNA's Return On Equity of -22.62% is amongst the best of the industry. RNA outperforms 84.86% of its industry peers.
Industry RankSector Rank
ROA -20.61%
ROE -22.62%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
RNA Yearly ROA, ROE, ROICRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

RNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNA Yearly Profit, Operating, Gross MarginsRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNA has been increased compared to 1 year ago.
Compared to 5 years ago, RNA has more shares outstanding
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNA Yearly Shares OutstandingRNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RNA Yearly Total Debt VS Total AssetsRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RNA has an Altman-Z score of 14.80. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RNA (14.80) is better than 92.61% of its industry peers.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.8
ROIC/WACCN/A
WACC10.28%
RNA Yearly LT Debt VS Equity VS FCFRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 15.73 indicates that RNA has no problem at all paying its short term obligations.
RNA's Current ratio of 15.73 is amongst the best of the industry. RNA outperforms 91.73% of its industry peers.
RNA has a Quick Ratio of 15.73. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
RNA's Quick ratio of 15.73 is amongst the best of the industry. RNA outperforms 91.73% of its industry peers.
Industry RankSector Rank
Current Ratio 15.73
Quick Ratio 15.73
RNA Yearly Current Assets VS Current LiabilitesRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.34% over the past year.
RNA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.95%.
RNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.26% yearly.
EPS 1Y (TTM)0.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
Revenue 1Y (TTM)13.95%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%35.57%

3.2 Future

RNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.40% yearly.
The Revenue is expected to grow by 168.92% on average over the next years. This is a very strong growth
EPS Next Y-36.18%
EPS Next 2Y-24.45%
EPS Next 3Y0.5%
EPS Next 5Y27.4%
Revenue Next Year-26.63%
Revenue Next 2Y31.4%
Revenue Next 3Y228.41%
Revenue Next 5Y168.92%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RNA Yearly Revenue VS EstimatesRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
RNA Yearly EPS VS EstimatesRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNA Price Earnings VS Forward Price EarningsRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNA Per share dataRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y0.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVIDITY BIOSCIENCES INC

NASDAQ:RNA (4/22/2025, 8:00:01 PM)

Premarket: 30 +0.55 (+1.87%)

29.45

+0.93 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners107.03%
Inst Owner Change0.18%
Ins Owners0.89%
Ins Owner Change2.72%
Market Cap3.54B
Analysts82.35
Price Target68.18 (131.51%)
Short Float %15.04%
Short Ratio12.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.75%
Min EPS beat(2)-0.04%
Max EPS beat(2)9.54%
EPS beat(4)2
Avg EPS beat(4)6.83%
Min EPS beat(4)-0.83%
Max EPS beat(4)18.66%
EPS beat(8)5
Avg EPS beat(8)6.16%
EPS beat(12)8
Avg EPS beat(12)4.57%
EPS beat(16)10
Avg EPS beat(16)1.75%
Revenue beat(2)1
Avg Revenue beat(2)23.63%
Min Revenue beat(2)-45.8%
Max Revenue beat(2)93.05%
Revenue beat(4)2
Avg Revenue beat(4)15.25%
Min Revenue beat(4)-45.8%
Max Revenue beat(4)93.05%
Revenue beat(8)5
Avg Revenue beat(8)5.64%
Revenue beat(12)8
Avg Revenue beat(12)5.45%
Revenue beat(16)11
Avg Revenue beat(16)15.69%
PT rev (1m)-0.77%
PT rev (3m)-2.09%
EPS NQ rev (1m)2.34%
EPS NQ rev (3m)-21.9%
EPS NY rev (1m)-17.95%
EPS NY rev (3m)-20.19%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)-46.96%
Revenue NY rev (1m)-2.62%
Revenue NY rev (3m)-10.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 324.88
P/FCF N/A
P/OCF N/A
P/B 2.48
P/tB 2.48
EV/EBITDA N/A
EPS(TTM)-2.89
EYN/A
EPS(NY)-3.94
Fwd EYN/A
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.5
OCFYN/A
SpS0.09
BVpS11.85
TBVpS11.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.61%
ROE -22.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 254.54%
Cap/Sales 64.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.73
Quick Ratio 15.73
Altman-Z 14.8
F-Score4
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
EPS Next Y-36.18%
EPS Next 2Y-24.45%
EPS Next 3Y0.5%
EPS Next 5Y27.4%
Revenue 1Y (TTM)13.95%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%35.57%
Revenue Next Year-26.63%
Revenue Next 2Y31.4%
Revenue Next 3Y228.41%
Revenue Next 5Y168.92%
EBIT growth 1Y-60.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.8%
EBIT Next 3Y6.26%
EBIT Next 5YN/A
FCF growth 1Y-149.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.7%
OCF growth 3YN/A
OCF growth 5YN/A